|Bid||3.7500 x N/A|
|Ask||3.9000 x N/A|
|Day's Range||3.6800 - 3.9000|
|52 Week Range||0.4150 - 5.9900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 14, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that MindMed's Chief Executive Officer, Robert Barrow, will be leading a roundtable discussion at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit.
More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges.
MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in helping healthcare organizations safely connect their data, announced a partnership through which MindMed will use Datavant's privacy-protecting technology to link MindMed's clinical trial data to external data from both clinical and real-world sources. MindMed plans to use Datavant's linking technology across various stages of the drug lif